ROKIT HEALTHCARE is a global healthcare company committed to providing an effective autologous organ regeneration platform using its proprietary biofabrication technologies across all types of applicable diseases in the field of regenerative medicine.

Through a convergence of know-how’s and innovation in the areas of R&D (i.e. 4D bioprinting, autologous stem cell technologies, and human-derived biomaterials), surgical medicine, and regulatory affairs, ROKIT Healthcare believes in supplying customized organ regeneration platform services that will drastically change the way we trust and manage the health of our own body.

2012 ROKIT, Inc. established
2016 Biofabrication device ‘ROKIT INVIVO’ launched
2017 ROKIT EU established collaboration with Fraunhofer IBMT
2018. 1. Collaboration with domestic medical institutions
2018. 7. Appointed as the lead underwriter for IPO
2018. 9. Name change to ROKIT Healthcare, Inc
2018. 11. Attended ISAP to announce Clinical research data from Skin Regeneration Platform
2019. 5. Closing of $27 million in a Domestic Series B round
2019. 7. ROKIT America, Inc. established
2019. 10 ROKIT Healthcare Launching Show
2019. 11. · Proceeded Cartilage Regeneration Pre-clinical Study at Massachusetts General Hospitals(MGH) · Won Tech Challenge award as a breakthrough technology company from AAPS (American Association of Pharmaceutical Scientists)
2019. 12. Nominated as the top healthcare company from IFAH(International Forum on Advancements in Healthcare)
2020. 04. Start DFURegen Clinical Trial in Korea
2020. 07. DRADS Capital Investment where Dr. Rudolph E. Tanzi. Ph.d. a confounder

Rokit - Meniscus Half Tissue Allograft

Products Details